Table 1

Physicians’ responses regarding how hypothetical patients receiving first-line treatment for chronic-phase CML would be managed based on BCR-ABL levels.

% of respondents	Physicians’ response (N=41)

	Immediately switch	Re-evaluate in 30–60 days	Will not switch
ELN-defined optimal response [7]
BCR-ABL level of <0.1% with residual disease at 24 mo
Korea	7	27	66
ROW	18	28	53
ELN-defined suboptimal response [7]
BCR-ABL level of >10% at 3 mo
Korea	5	66	29
ROW	15	55	29
BCR-ABL level of 1–10% at 6 mo
Korea	2	61	37
ROW	13	51	35
BCR-ABL level of 0.1–1% at 12 mo
Korea	2	63	34
ROW	14	52	33
ELN-defined treatment failure [7]
BCR-ABL level of >10% at 6 mo
Korea	76	15	10
ROW	76	20	4
BCR-ABL level of >1% at 12 mo
Korea	73	17	10
ROW	74	20	6

Abbreviations: CML, chronic myeloid leukemia; ELN, European LeukemiaNet; ROW, rest of the world.

Blood Res 2021;56:31~37 https://doi.org/10.5045/br.2021.2020260